Literature DB >> 12109910

N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands.

Rosaria Volpini1, Stefano Costanzi, Catia Lambertucci, Sara Taffi, Sauro Vittori, Karl-Norbert Klotz, Gloria Cristalli.   

Abstract

A series of N(6)-alkyl-2-alkynyl derivatives of adenosine (Ado) have been synthesized and evaluated for their affinity at human A(1), A(2A), and A(3) receptors and for their potency at A(2B) adenosine receptor subtypes. The corresponding 2-(1-alkynyl) derivatives of 5'-N-ethylcarboxamidoadenosine (NECA) and Ado are used as reference compounds. Binding studies demonstrated that the activities of 2-alkynylAdos were slightly increased for the adenosine A(1) receptor and slightly decreased for both A(3) and A(2B) subtypes compared to those of their corresponding NECA derivatives, whereas the A(2A) receptor affinities of the two series of nucleosides were similar. The presence of a methyl group on N(6) of the 2-alkynyladenosines, inducing an increase in affinity at the human A(3) receptor and a decrease at the other subtypes, resulted in an increase in A(3) selectivity. In particular, 2-phenylethynyl-N(6)-methylAdo (8b) showed an A(3) affinity in the low nanomolar range (K(i)(A(3)) = 3.4 nM), with a A(1)/A(3) and A(2A)/A(3) selectivity of about 500 and 2500, respectively. These findings motivated us to search for the preparation of new selective radioligands for the A(3) subtype; hence, a procedure to introduce a tritiated alkylamino group in these molecules was carried out. As far as the potency at the A(2B) receptor, the type of 2-alkynyl chain and the presence of the ethylcarboxamido group on the sugar seem to be very important; in fact, the (S)-2-phenylhydroxypropynylNECA [(S)-PHPNECA, 1e, EC(50)(A(2B)) = 0.22 microM] proved to be one of the most potent A(2B) agonist reported so far. On the other hand, the (S)-2-phenylhydroxypropynyl-N(6)-ethylAdo (9e, EC(50)(A(2B)) = 0.73 microM) showed a significantly increase of potency at the A(2B) subtype in comparison with the N(6)-methyl, N(6)-isopropyl, and the unsubstituted adenosine derivatives, although it resulted in being less potent than (S)-PHPNECA (1e, EC(50)(A(2B)) = 0.22 microM). These observations suggest that the introduction of an ethyl group in the N(6)-position and an ethylcarboxamido substituent in the 4'-position of (S)-2-phenylhydroxypropynyladenosine could lead to a compound endowed with high potency at the A(2B) receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12109910     DOI: 10.1021/jm0109762

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

1.  Chapter 13. A3 Adenosine Receptors.

Authors:  Kenneth A Jacobson; Susanna Tchilibon; Bhalchandra V Joshi; Zhan-Guo Gao
Journal:  Annu Rep Med Chem       Date:  2003       Impact factor: 1.059

2.  A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists.

Authors:  Kenneth A Jacobson; Michihiro Ohno; Heng T Duong; Soo-Kyung Kim; Susanna Tchilibon; Michal Cesnek; Antonín Holý; Zhan-Guo Gao
Journal:  Chem Biol       Date:  2005-02

3.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

Review 4.  Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.

Authors:  Kenneth A Jacobson; Athena M Klutz; Dilip K Tosh; Andrei A Ivanov; Delia Preti; Pier Giovanni Baraldi
Journal:  Handb Exp Pharmacol       Date:  2009

Review 5.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

6.  Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor.

Authors:  Hayamitsu Adachi; Krishnan K Palaniappan; Andrei A Ivanov; Nathaniel Bergman; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2007-03-23       Impact factor: 7.446

7.  9-Ethyladenine derivatives as adenosine receptor antagonists: 2- and 8-substitution results in distinct selectivities.

Authors:  Karl-Norbert Klotz; Sonja Kachler; Catia Lambertucci; Sauro Vittori; Rosaria Volpini; Gloria Cristalli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-07       Impact factor: 3.000

8.  Recent improvements in the development of A(2B) adenosine receptor agonists.

Authors:  Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Francesca Fruttarolo; Romeo Romagnoli; Delia Preti
Journal:  Purinergic Signal       Date:  2009-01-31       Impact factor: 3.765

9.  Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position.

Authors:  Michihiro Ohno; Zhan-Guo Gao; Philippe Van Rompaey; Susanna Tchilibon; Soo-Kyung Kim; Brian A Harris; Ariel S Gross; Heng T Duong; Serge Van Calenbergh; Kenneth A Jacobson
Journal:  Bioorg Med Chem       Date:  2004-06-01       Impact factor: 3.641

10.  2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors.

Authors:  Zhan-Guo Gao; Liaman K Mamedova; Peiran Chen; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2004-11-15       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.